Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS

Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03316469

Enrollment

Registered

2017-10-20

Start date

2018-07-31

Completion date

2018-12-31

Last updated

2018-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

Anti-mullerian hormone

Brief summary

Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It affects women's reproductive capability; thus patients have risks of infertility, miscarriage, and complicated pregnancy. A study revealed that the prevalence of oligoovulation or anovulation in patients with PCOS ranged from 65% to 80%. Anti-Mullerian Hormone (AMH) is an important regulator in the ovary that play a rule during development and function. It is suspected to affect clomiphene citrate (cc) resistance. In this study the investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS.

Interventions

DRUGClomiphene Citrate

100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods

DIAGNOSTIC_TESTFollicular growth

Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Women diagnosed with PCOS * Women 20-35 years old. * BMI ≤30 kg/m without previous ovulation induction. * Partners with normal semen parameters Parameter World Health Organization (WHO) 2010 Volume1.5 ml Concentration 15 million/ml Progressive motility 32% Normal forms 4%

Exclusion criteria

* Women with evidence of hyper-or hypothyroidism, hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia or androgen-secreting tumors. * Women with factors of infertility other than PCOS * Women with incomplete data.

Design outcomes

Primary

Measure	Time frame	Description
AMH in prediction of Ovulation in women with PCOS.	10 days	AMH level is measured 10 days before expected date of ovulation then correlated to ovulation either successfully or not.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026